Alpha Teknova (TKNO) vs Xeris Biopharma (XERS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Alpha Teknova (TKNO) has outperformed Xeris Biopharma (XERS) over the past year, gaining 58.9% versus a gain of 24.3%. Over five years, XERS leads with a +409.5% price change compared with -63.5% for TKNO. Xeris Biopharma is the larger company by market cap ($1.91 billion vs $478.4 million), about 4.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | TKNO | XERS |
|---|---|---|
| Share price | $8.91 | $10.50 |
| Market cap | $478.36M | $1.91B |
| 1-day change | +5.57% | +2.99% |
| YTD return | +122.11% | +29.81% |
| 1-year return | +58.95% | +24.27% |
| 5-year return | -63.46% | +409.50% |
| Forward P/E | — | 28.36 |
| EPS (TTM) | $-0.31 | $-0.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $291.85M |
| Revenue growth (YoY) | — | +43.72% |
| Net income (latest FY) | — | $554.00K |
| Gross margin | — | 85.41% |
| Operating margin | — | 8.53% |
| Net margin | — | 0.19% |
| 52-week high | $9.48 | $11.33 |
| 52-week low | $1.91 | $5.25 |
| Distance from 52-week high | -6.01% | -7.37% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +1.01% | +22.53% |
| Average volume | 232.69K | 2.17M |
| Shares outstanding | 53.69M | 182.32M |
| Employees | 158 | 435 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Xeris Biopharma is about 4.0 times larger than Alpha Teknova by market value ($1.91B vs $478.36M).
- TKNO has outperformed XERS by 34.7 percentage points over the past year.
About Alpha Teknova
TKNO stock →Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 158 employees
About Xeris Biopharma
XERS stock →Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 435 employees
TKNO vs XERS FAQ
Which is bigger, Alpha Teknova or Xeris Biopharma?
Xeris Biopharma (XERS) is larger, with a market capitalization of $1.91B compared with $478.36M for Alpha Teknova (TKNO).
Which stock has performed better over the past year, TKNO or XERS?
TKNO returned +58.95% over the past 12 months, compared with +24.27% for XERS (price return, excluding dividends). Past performance does not predict future results.
Are Alpha Teknova and Xeris Biopharma in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: In Vitro & In Vivo Diagnostic Substances for Alpha Teknova and Biotechnology: Pharmaceutical Preparations for Xeris Biopharma.